NRAD1: A Critical Enzyme in Detoxifying Xenobiotics (G121838)

Target Name: NRAD1

NCBI ID: G121838

NRAD1

Other Name(s): Non-coding RNA in the aldehyde dehydrogenase 1A pathway | LINC00284 | non-coding RNA in the aldehyde dehydrogenase 1A pathway | NCRNA00284

NRAD1: A Critical Enzyme in Detoxifying Xenobiotics

The aldehyde dehydrogenase 1A (NRAD1) pathway is a critical antioxidant enzyme that is involved in the detoxification of xenobiotics and other harmful substances in the body. This enzyme is located in the nuclear envelope of the cell and its function is to convert various xenobiotics, including xenobiotics that are foreign to the body, into less toxic forms.NRAD1 is a non-coding RNA molecule that plays a crucial role in the regulation of this critical pathway.

The NRAD1 pathway is a complex series of chemical reactions that involve the detoxification of xenobiotics. The first step in the pathway is the production of reactive oxygen species (ROS) by the oxidation of various cellular organelles. These ROS generate reactive intermediates that require the intervention of NRAD1.

NRAD1 functions as a critical enzyme in the detoxification of xenobiotics by converting them into less toxic forms. It does this by participating in the oxidation of the ROS generated by the previous step. The resulting less toxic intermediates are then processed further to produce the final products of the pathway, which include water and a carbon dioxide.

NRAD1 is a key enzyme in the detoxification of xenobiotics and its function is critical for the survival of the cell. It is well established that exposure to xenobiotics can cause oxidative stress and DNA damage, leading to the development of various diseases, including cancer. Therefore, the study of NRAD1 and its function in the detoxification of xenobiotics is of great interest.

Drugs that target NRAD1 have the potential to be developed as therapeutic agents for various diseases, including cancer. For example, studies have shown that inhibitors of NRAD1 have the potential to inhibit the growth of cancer cells and to cause apoptosis (programmed cell death) in these cells. Therefore, NRAD1 is a drug target of great interest and further research is needed to understand its function and the potential of its inhibitors.

NRAD1 is also a biomarker that can be used to diagnose and monitor various diseases. For example, the production of ROS by the NRAD1 pathway is increased in response to the presence of certain xenobiotics, such as those that cause oxidative stress. Therefore, the level of ROS produced by NRAD1 can be used as a diagnostic tool for certain diseases.

NRAD1 is a non-coding RNA molecule that plays a crucial role in the detoxification of xenobiotics and its function is critical for the survival of the cell. Its inhibition has the potential to be a therapeutic agent for various diseases, including cancer. Further research is needed to understand its function and the potential of its inhibitors. TheNRAD1 pathway is a complex series of chemical reactions that involve the detoxification of xenobiotics and its function is critical for the survival of the cell. The inhibition of NRAD1 has the potential to be a therapeutic agent for various diseases, including cancer.

Protein Name: Non-coding RNA In The Aldehyde Dehydrogenase 1A Pathway

The "NRAD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NRAD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets